Daiichi Sankyo Q2 FY2026 slides: oncology surge drives record growth

Daiichi Sankyo reported fiscal Q2 revenue up 19.7% year over year to ¥1,167.2 billion and core operating profit up 46.9% to ¥221.3 billion; EPS of ¥45.5 beat the ¥39.81 forecast by 14.3%. ENHERTU sales rose 45.9% to ¥464.5 billion, and DATROWAY sales more than tripled to ¥48.3 billion; the company raised its full-year ENHERTU forecast by ¥20.5 billion while keeping total FY2026 revenue guidance at ¥2,340.0 billion. Shares rose 5.21% following the presentation. Positive trial results, expanding approvals and a five-year operational program targeting more than ¥200 billion in cumulative benefits support the growth outlook, though restructuring costs and seasonal fourth-quarter headwinds remain.

Analysis

The key read-through is positive for AstraZeneca (AZN), but narrower than the headline growth suggests: ENHERTU demand and new indications support partner economics, while the article does not disclose the split of incremental profit or how much of the good news is already priced. The stronger near-term signal is clinical breadth—first-line HER2-mutant lung cancer data could extend the drug’s addressable market—rather than one quarter’s yen-reported growth, which was materially aided by currency translation. Verify AZN’s reported alliance revenue and guidance before sizing a position.

For Summit Therapeutics (SMMT), the DATROWAY/ivonescimab collaboration is an option, not current earnings support: shared trial costs and retained product rights limit near-term economics, while Phase 3 efficacy, safety, and execution remain unproven. The collaboration may add validation to the combination strategy, but does not establish commercial value for SMMT.

Over 1–3 months, watch DATROWAY’s expected TROPION-Lung15 readout and AZN commentary on ENHERTU demand and alliance contributions. Over 6–18 months, multiple Phase 3 readouts and launch execution matter more than Daiichi Sankyo’s operational-savings target, which is aspirational and requires delivery. The bullish consensus may underweight concentration in the DXd platform, competition, and tolerability risks, including interstitial lung disease. Also reconcile the article’s differing ENHERTU forecast figures and product-sales versus portfolio-revenue scopes before using them in valuation work.

Key Decisions for Investors

• AZN: Maintain a modest positive bias; add only on weakness or after confirming that ENHERTU alliance economics and guidance translate into incremental earnings. Thesis weakens if AZN lowers oncology guidance or reports slowing ENHERTU uptake in key indications.
• SMMT: Treat the collaboration as a catalyst watch, not a standalone buy signal. Reassess around TROPION-Lung15 and subsequent combination-trial details; require evidence of efficacy and a credible development timeline before paying for optionality.
• Daiichi Sankyo: Avoid extrapolating yen-reported growth directly into constant-currency earnings. Track CMO compensation reversals, fourth-quarter seasonality, and whether margin gains persist after FX and partner-payment effects.
• Risk control: Reduce exposure if pivotal studies disappoint, safety signals worsen, or competing therapies materially erode uptake; near-term positive sentiment alone is not a sufficient entry trigger.